Charles River Immunology Services

Advances in immunology research have clarified the role the immune system plays in many disease areas, even those that have not been traditionally thought of as having an immune component. We are committed to providing solutions for the discovery and development of new medicines and in 2019, supported the development of approximately 85% of the drugs approved by the FDA. Our goal is to provide the utmost in terms of service and quality, so that your research teams can focus on what matters most — finding cancer and auto immune disease cures.

View Webinars

technician holding a mouse model

To help you develop the best translational path for your therapeutics, we have gathered information about our relevant services, special offers, resources, and contact details. In addition, we offer research models and associated services as well as immunology endpoints.

We can create your transgenic mouse and rat model. Charles River helps clients select, customize, create, and maintain the right model for their studies using the latest technologies. Our expert staff can work with you from concept to model creation to deliver the research animals you require for your studies. View videos
We can can help to get vaccines to market. With decades of experience supporting the vaccine industry, our global network of scientific and regulatory experts provides vaccine developers with the right expertise early in the development process to boost productivity, efficiency, and profitability, and get the safest and most effective vaccines to market. Ask an expert
We can de-risk your preclinical candidates using predictive immunotoxicology. Due to the intrinsic complexity of the predictive immunotoxicology assessments, definite designs are not rigidly specified. This white paper will help you to drive your program through this requirement and challenges in delivering an appropriate set of assessments for regulatory review. Download white paper
We offer contract breeding of genetically engineered mice and rats. Charles River provides a full-service rodent colony management program to deliver transgenic animals to you when you need them, in the exact quantities you specify, and with the health status that you require. Learn more
We provide customized workplace solutions. Offering staffing, training, consulting and other animal facility support services - we help clients streamline their drug discovery and development programs to make best use of their resources and achieve optimum results. Learn more

Animal models, translational immunology assays, autoimmune and inflammation models that accurately reflect the human immune system are powerful tools to advance your immunology research. ​

Animal models for disease studies Charles River maintains a comprehensive portfolio of animal models specific for studying diseases. Further, through our preconditioning services, we can offer an array of surgical procedures, so that you receive your animal study ready. Find a model
Which animal model is right for your study? Our animal model evaluation program allows you to assess the quality and compatibility of our animal models at no cost before making a commitment. Learn more
Immunology and inflammation models  Our expert immunologists and microbiologists can support your immunology programs with a wide selection of in vivo and in vitro immunology assays, immuno-oncology assays, inflammation, autoimmune and infection models, across numerous therapeutic areas, including vaccine development, infectious disease, immuno-oncology, neuro-inflammation and fibrosis. Explore these models
Highly immunodeficient mice Animal Models can contribute invaluable information to the discovery and development of new drug. Besides standard strains such as C57BL/6, BALB/c or CD-1, Charles River exclusively offers the most immunodeficient NSG® with possibilities for humanization. Find an immunodeficient model
Requirements for immunology safety assessments Our animal model evaluation program allows you to assess the quality and compatibility of our animal models at no cost before making a commitment. Learn more
Immunology and inflammation models  Assessment of immune endpoints will be required for any therapeutic which is either designed to modulate immune function or belongs to a class of compounds with known immunomodulatory potential. The ICH S8 & ICH S6(R1) guideline for human pharmaceuticals with immunomodulatory actions recommends a weight-of-evidence approach to assess potential immunotoxicity risk. Additional immunotoxicity endpoints reflecting the mechanism of action of the compound should be included within study designs, as immunophenotyping, cytokine measurements, in vitro immunology testing, TDAR assay or Immunogenicity assessment. At Charles River, you’ll find a dedicated multidisciplinary team of global immunologists, statisticians and drug development experts who can help you devise the best strategy for your therapeutic so you can move forward to IND and monitor your drug in clinic.
Pharmacodynamic biomarkers Incorporating proof of mechanism endpoints into early clinical trials, which are traditionally run only for safety endpoints, means pharmacodynamic (PD) biomarker assays can confirm target engagement in first in human studies, improving your chances of moving to Phase III. Charles River can customize PD biomarker assays to support go/no-go decisions for your program.
Clinical research In the clinical phase, immunology assays become critical for almost all advanced therapeutics – from small molecules, monoclonal antibodies (mAbs) for oncology, through vaccine programs, microbiome, as well as gene and cell therapies. Clinical immunological assays will be required for any therapeutic that might trigger an immune response to ensure the response doesn’t compromise patient safety. Our expertise can help you choose the right tools to analyze samples from multicenter clinical trials.
Seminars and virtual seminars •  Understanding Immune Mechanisms: The Key to Vaccine Efficacy and Safety
•  The Yin & Yang of T Cell Function: Advancing Autoimmune and IO Therapies
Videos •   Revolutionizing the Way We Treat Disease
•   Immunophenotyping – Can't Miss Endpoints for Safety Assessment
Literature •    Advancing Oncology & Immuno-Oncology Research Using NSG® Mice Whitepaper
•    Immunodeficient Models Xenograft Data Collection 
•    The CORE (Collection of Oncology Research Experiments)
•    Surgery Model Utilizations in Oncology
•    Immunology infographic
•    Immunology services and facilities datasheet
Other resources Our specialists can also provide customized educational virtual or on-site seminars at no cost on a variety of topics including:
•    Model creation 
•    Comparing immunodeficient mice for cancer research
•    Scientific reproducibility, biosecurity and the 3rs – determining how to acquire animal models
•    View other resources

DOT content TK?

Missing contact info